A Blog Devoted to UD Innovation, Excellence & Scholarship
Precision Prevention for Prostate Cancer
Aditya Dutta and research collaborators found that, under conditions of stress, the NKX3.1 gene, which is critical in prostate biology, moves to the mitochondria — the powerhouse of the cell — in order to protect against prostate cancer.
The University of Delaware’s Aditya Dutta and collaborators are investigating the NKX3.1 gene and its role in prostate cancer — the most common cancer and the second-leading cause of cancer-related death among men in the United States.
In prostate biology, NKX3.1 is big. The gene regulates everything — development, maintenance, disease initiation and progression.
In a new research article published in Cancer Discovery, the researchers found that, under conditions of stress, NKX3.1 moves to the mitochondria — the powerhouse of the cell — in order to protect against prostate cancer. Mitochondria play a pivotal role in stress responses.
“Mitochondria are like the canary in the coal mine,” said Dutta, a UD assistant professor with appointments in both the Department of Animal and Food Sciences as well as the Department of Biological Sciences. “They act as stress sensors and lead the cell’s response to stress.”
Most patients diagnosed with prostate cancer are put on active surveillance. Close monitoring determines exactly when their cancer will become aggressive. This study’s results are promising for these patients. Microscopic histological analysis for NKX3.1 will allow for a precision prevention approach, helping patients determine their risk for progression to aggressive disease.
“The role of NKX3.1 in prostate cancer has been known for over two decades; however, its role was limited to its function in the nucleus of the cell,” Dutta said. “Our analysis of NKX3.1 in animal models and human prostate specimens indicated the gene’s presence outside the nucleus, specifically in the mitochondria.”
NKX3.1 and prostate cancer risk
NKX3.1 is a master regulator that undergoes functional loss in up to 80% of early-stage prostate cancers. Analyses show that loss of NKX3.1 is the initiating event in the evolution of prostate cancer. Additionally, prostate cancer aggressiveness in African-American men is linked to reduced levels of NKX3.1. The researchers identified the lack of NKX3.1 mitochondrial function in two mutations associated with increased risk of aggressive prostate cancer, highlighting the potential use of NKX3.1 non-nuclear localization as a tool for risk assessment in prostate cancer.
“This means that we can look for NKX3.1 outside the nucleus, and, if it’s indeed found outside, your odds of developing aggressive disease go up significantly,” Dutta said. “You need treatment right away.”